Cardiology’s April Plot Twists Revealed

April was wild for heart health news! VERVE-102 gene therapy got FDA Fast Track status after slashing LDL-C by up to 70% in early trials—major hope for high cholesterol. Meanwhile, mavacamten stumbled in a big trial for non-obstructive HCM, but the FDA made it easier to use for obstructive HCM. Plus, combo cholesterol meds are saving more lives post-heart attack, and a new pacemaker tech just got Breakthrough Device status. Cardiology is seriously leveling up! #Cardiology #GeneTherapy #FDAnews #HeartHealth #MedicalInnovation #Health